None
Quote | IDEAYA Biosciences Inc. (NYSE:IDYA)
Last: | $ |
---|---|
Change Percent: | 1.34% |
Open: | $6.60 |
Close: | $6.82 |
High: | $6.95 |
Low: | $6.60 |
Volume: | 34,610 |
Last Trade Date Time: | 02/12/2020 04:41:43 pm |
News | IDEAYA Biosciences Inc. (NYSE:IDYA)
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study PR Newswire Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024 , at 9:51 AM CDT The abstract summary wil...
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer PR Newswire Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on...
Message Board Posts | IDEAYA Biosciences Inc. (NYSE:IDYA)
Subject | By | Source | When |
---|---|---|---|
$THER STOCK CANCER GOOD NEWS | Jayzp | investorshub | 04/24/2023 12:39:39 PM |
Finally some pub. Just take something to | Poshfox | investorshub | 09/02/2020 10:49:52 PM |
$60 million becomes $100 offering. | Laster | investorshub | 06/18/2020 2:07:55 AM |
POS company gets $100 million and then announces | Laster | investorshub | 06/17/2020 12:26:28 AM |
Awesome press release, lets see where this goes | dinogreeves | investorshub | 06/16/2020 12:19:43 PM |
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study PR Newswire Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024 , at 9:51 AM CDT The abstract summary wil...
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer PR Newswire Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on...
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , April 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and...